Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction.

The aim of this study was to set up a method for quantification of plasma mitomycin C (MMC) concentrations during intravesical chemotherapy delivered in the presence of local bladder hyperthermia (HT). In comparison with existing methods, this assay, characterized by relative simplicity and efficiency, resulted in the facilitation of performance with nondedicated instrumentation or nonspecialized staff. Purification from plasma matrix was carried out by solid-phase extraction under vaccuum. The purified drug was then collected directly into the vials of the HPLC autosampler. Chromatographic analysis was performed on a reversed-phase C18 column with water:acetonitrile (85:15 by vol) as the mobile phase and the UV detector set at 365 nm. The use of porfiromycin as internal standard provided a method with good within-day precision (CV 6.0% at 5 micrograms/L, n = 6), linearity (0.5-50 micrograms/L), and specificity. The lower limit of detection (< or = 0.5 microgram/L) proved to be suitable for plasma pharmacokinetics monitoring in two tested patients treated with MMC + HT for superficial bladder cancer.

[1]  S. Crooke,et al.  Mitomycin C. , 1976, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man.

[2]  K. Ensing,et al.  Determination of mitomycin C in plasma, serum and urine by high-performance liquid chromatography with ultra-violet and electrochemical detection. , 1982, Journal of chromatography.

[3]  J. Dalton,et al.  High-performance liquid chromatographic determination of mitomycin C in rat and human plasma and urine. , 1989, Journal of chromatography.

[4]  F. Torti,et al.  Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. , 1991, Journal of the National Cancer Institute.

[5]  P. Rigatti,et al.  Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. , 1996, The Journal of urology.

[6]  J. Hartigh,et al.  High-performance liquid chromatographic determination of the antitumor agent mitomycin c in human blood plasma , 1981 .

[7]  J. van der Greef,et al.  Automated analysis of mitomycin C in body fluids by high-performance liquid chromatography with on-line sample pre-treatment. , 1987, Journal of chromatography.

[8]  H. Pinedo.  Cancer chemotherapy 1979 , 1979 .

[9]  K. Fujiwara,et al.  Enzyme immunoassay for the quantification of mitomycin C using beta-galactosidase as a label. , 1982, Cancer research.

[10]  S. Crooke,et al.  Phase I study of oral mitomycin C. , 1976, Cancer treatment reports.

[11]  P. Rigatti,et al.  A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. , 1995, The Journal of urology.

[12]  N. Bachur,et al.  Liquid chromatographic and mass spectral analysis of mitosane and mitosene derivatives of mitomycin c , 1983 .

[13]  H. Fujita.  Comparative Studies on the Blood Level, Tissue Distribution, Excretion and Inactivation of Anticancer Drugs , 1971 .

[14]  H. Huland,et al.  Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. , 1990, The Journal of urology.